Evidence map›Paper›PMID 35096788›Full record

ArticleFrontiers in bioengineering and biotechnology2021

From the Discovery of Extremozymes to an Enzymatic Product: Roadmap Based on Their Applications.

Giannina Espina, Sebastián A Muñoz-Ibacache, Paulina Cáceres-Moreno, Maximiliano J Amenabar, Jenny M Blamey

Open access · goldAbstract read
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
6.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Lipase production fromFrontiers in microbiology · 2025
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Extreme Biocatalysts: From Basic Research to Biotechnological Applications.International journal of molecular sciences · 2024
    Article
  14. Review
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Giannina EspinaFundación Biociencia, Santiago, Chile.
Sebastián A Muñoz-IbacacheFundación Biociencia, Santiago, Chile.
Paulina Cáceres-MorenoFundación Biociencia, Santiago, Chile.
Maximiliano J AmenabarFundación Biociencia, Santiago, Chile.
Jenny M BlameyFundación Biociencia, Santiago, Chile.
Fundación Chile · CLUniversidad de Santiago de Chile · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the advent of the industrial revolution, the use of toxic compounds has grown exponentially, leading to a considerable pollution of the environment. Consequently, the development of more environmentally conscious technologies is an urgent need. Industrial biocatalysis appears as one potential solution, where a higher demand for more robust enzymes aims to replace toxic chemical catalysts. To date, most of the commercially available enzymes are of mesophilic origin, displaying optimal activity in narrow ranges of temperature and pH (i.e., between 20°C and 45°C, neutral pH), limiting their actual application under industrial reaction settings, where they usually underperform, requiring larger quantities to compensate loss of activity. In order to obtain novel biocatalysts better suited for industrial conditions, an efficient solution is to take advantage of nature by searching and discovering enzymes from extremophiles. These microorganisms and their macromolecules have already adapted to thrive in environments that present extreme physicochemical conditions. Hence, extremophilic enzymes stand out for showing higher activity, stability, and robustness than their mesophilic counterparts, being able to carry out reactions at nonstandard conditions. In this brief research report we describe three examples to illustrate a stepwise strategy for the development and production of commercial extremozymes, including a catalase from an Antarctic psychrotolerant microorganism, a laccase from a thermoalkaliphilic bacterium isolated from a hot spring and an amine-transaminase from a thermophilic bacterium isolated from a geothermal site in Antarctica. We will also explore some of their interesting biotechnological applications and comparisons with commercial enzymes.

Indexed as

amine-transaminaseAntarcticabiocatalystscatalaseextremophileslaccase

Identifiers

PMID35096788
PMCPMC8790482
OpenAlexW4206775835

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.